Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer is a phase 2, interventional study registered as NCT05841134 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 25 participants, started 2023-06-01 and due to reach its primary completion in 2024-12-31. Interventions recorded: Tislelizumab. Conditions listed: MSI-H Colorectal Cancer; Tislelizumab; Oxaliplatin; Capecitabine. Primary outcome: Percentage of Participants With Pathological Complete Response (pCR). Colorectal eligibility wording from the registry: "Patients with colon or rectal adenocarcinoma confirmed by histology or cytology;". No results are recorded here; the registry entry is the source.